Clinical Trial

Sequential Study of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
PSMA is an ideal target for the precise diagnosis and treatment of prostate cancer. LNC1011 is a novel albumin-binding PSMA-targeted compound. This study aims to investigate the safety and efficacy of different doses of 225Ac-labeled LNC1011 in the treatment of patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) and to explore the optimal therapeutic dose.
Trial Details
NCT Number NCT07363486
Lead Sponsor First Affiliated Hospital of Fujian Medical University
Conditions Prostate Cancer
Enrollment 9 participants
Start Date 2025-04-01
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-01-23